Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate

Oskar Ragnarsson1, Gudmundur Johannsson, Kjell Geterud

  • 1Department of Endocrinology, Diabetes and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden. oskar.ragnarsson@medic.gu.se

BMJ Case Reports
|August 15, 2013
PubMed

Insights

A previously undiagnosed mild form of congenital adrenal hyperplasia (CAH) can cause high testosterone levels after castration in prostate cancer patients. This endocrine disorder should be considered in such cases.

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Androgen deprivation therapy is a standard treatment for prostate cancer.
  • Maintaining low testosterone levels is crucial for effective management.

Observation:

  • A 69-year-old man with metastatic prostate cancer had persistently high testosterone levels post-castration.
  • Imaging revealed adrenal enlargement, and endocrine tests showed elevated adrenal androgens.

Findings:

  • Mutation analysis identified a non-classical 21-hydroxylase deficiency, a mild form of congenital adrenal hyperplasia (CAH).
  • This previously unreported cause of inadequate testosterone suppression was successfully managed with hydrocortisone and prednisolone.

Implications:

  • Undiagnosed non-classical CAH may affect treatment efficacy in prostate cancer patients.
  • Consider screening for CAH in men with prostate cancer experiencing suboptimal testosterone suppression after castration.